Sustainability in Inhaled Drug Delivery

• Published in: Pharmaceutical medicine Vol. 34; no. 3; pp. 191 - 199
• Main Authors: Wilkinson, Alexander J. K., Anderson, Greg
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.06.2020; Springer Nature B.V
• Subjects: Administration, Inhalation; Aerosol Propellants - adverse effects; Air pollution; Biomedical and Life Sciences; Biomedicine; Chlorofluorocarbons - adverse effects; Chronic obstructive pulmonary disease; Emissions; Equipment Design; Equipment Reuse; Greenhouse Effect; Greenhouse Gases - adverse effects; Humans; Leading Article; Metered Dose Inhalers - adverse effects; Outdoor air quality; Pharmaceutical Preparations - administration & dosage; Pharmaceutical Sciences/Technology; Pharmacology/Toxicology; Pharmacotherapy; Recycling; Sustainability; Sustainable Development; United Kingdom > UK
• ISSN: 1178-2595; 1179-1993
• DOI: 10.1007/s40290-020-00339-8

Asthma and chronic obstructive pulmonary disease (COPD) are amongst the most common chronic diseases worldwide, and are largely preventable by improving the quality of the air we breathe. The most commonly deployed treatment, the metered dose inhaler (MDI), uses hydrofluorocarbon propellants, which are powerful greenhouse gases that contribute disproportionately to the climate crisis. Alternative treatment strategies are required if we are to avoid contributing to the worst effects of climate change. These strategies include promoting non-pharmacological therapies like smoking cessation and pulmonary rehabilitation; empowering patients to gain better disease control through written management plans and encouraging preventer, rather than reliever therapies. Pharmacological strategies include: improving inhaler technique and spacer use; minimising propellant release by using smaller volume MDIs and simpler dosing regimes; dose counters to prevent waste; switching to low global warming potential inhalers; and inhaler recycling. There are also opportunities to improve disease control alongside reduced greenhouse gas emissions, including better matching of patients’ devices to inhaler technique rather than defaulting to MDIs, stopping unnecessary inhaled steroids in COPD and maintenance and reliever therapy in asthma. New, lower global warming potential propellants are on the horizon, and their introduction could offer a golden opportunity to enhance MDIs usability and sustainability by making them refillable, integrating whistles to optimise inhalation technique, adding integrated caps, optimising materials for recycling and adding dose counters to all MDIs.